English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Plasma androgen receptor ( AR ) copy number (CN) status identifies castration-resistant prostate cancer (CRPC) patients with worse outcome on abiraterone/enzalutamide. However, the impact of  AR  CN changes on clinical outcome in CRPC is unknown.   Materials and Methods:  Plasma samples from 73 patients treated with abiraterone or enzalutamide were collected at baseline and at the time of progression disease (PD). Droplet digital polymerase chain reaction was used to assess  AR  CN status.   Results:  We showed that 11 patients (15.1%) changed  AR  CN status from baseline to PD (9 patients from normal to gain, 2 from gain to normal). Patients changing  AR  CN status from normal at baseline to gain at PD had intermediate median overall survival (OS) of 20.5 months (95% CI = 8.0–44.2) between those who remained  AR  CN normal from baseline to PD (27.3 months [95% CI = 21.9–34.4]) and those who remained  AR  CN gain from baseline to PD (9.1 months [95% CI = 3.8–14.5],  p  < 0.0001). Patients changing  AR  CN from normal at baseline to gain at PD had a median progression-free survival (PFS) of 9.2 months (95% CI = 2.0–14.7), patients who remained  AR  CN normal had a median PFS of 9.1 months (95% CI = 7.2–10.1), and patients who remained  AR  CN gain had a median PFS of 5.4 (95% CI = 3.6–6.5,  p  = 0.0005). Both OS and PFS were not significantly different between patients with  AR  CN that changes from normal to gain and patients with stable  AR  CN normal.   Conclusions:  We showed that CRPC patients changing  AR  CN status from baseline to progression time point had intermediate OS and we suggested that  AR  CN evaluation at baseline could be the most informative for clinical outcome of CRPC patients treated with abiraterone or enzalutamide. Larger prospective studies are warranted.

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide